Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRAF p.V600E status confers therapeutic sensitivity to Trametinib in patients with Melanoma.
Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.
This statement is based on a regulatory approval from the Health Canada:
MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.